Vanarix SA

Vanarix offers off the shelf Cartibeads™ — allogeneic 3D cultured cartilage bio-implants to repair large knee defects.
• FDA orphan designation for osteochondritis dissecans. Key milestones achieved and action plans:
• Patented mass cell expansion in bioreactors: scalable and cost effective.
• Implants resemble native hyaline cartilage; target millions of patients.
• Pivotal Phase IIb/III trials planned 2027–2028; clinical supply via CDMO partners.
• Industrial plan: build automated 3D production sites for large scale, low cost manufacturing.
• Commercial rollout phased through orthopedic distributors, strategic clinical centers and KOLs.
• Funding sought to complete trials, prove cost effectiveness and target market launch in 2030.